Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Salestools Logo

Salestools

L'agente IA #1 per team di vendita e Go-to-Market. Vendi di più, più velocemente, con meno sforzo.

Prodotto

  • Agenti di vendita IA
  • Dati di intenzione
  • Dati Tecnologici
  • Tracciamento Visitatori
  • Co-Pilota
  • Vendita Sociale

Soluzioni

  • Servizio Clienti
  • E-commerce
  • SaaS
  • Impresa
  • Piccole Imprese

Risorse

  • Il rapporto
  • Documentazione
  • Riferimento API
  • Centro assistenza
  • Blog
  • Casi studio
  • Webinar

Azienda

  • Chi siamo
  • Carriere
  • Stampa
  • Contatto
  • Partner

Le nostre sedi

  • New York, HQ
  • Bucarest, Laboratorio di Ricerca IA
  • Zug, Svizzera

© 2026 Salestools. Tutti i diritti riservati.

Termini sui Dati e SicurezzaPolitica sulla privacyTermini di servizioAcceptable Use
Tutti i sistemi operativi
Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Back to Reports
Fundraising

Tango Therapeutics

Tango Therapeutics Raises $165M in Series B

100 Binney Street, Cambridge, MA 02142February 12, 20242 min read
Employees
120+

Tango Therapeutics Raises $165M in Series B


Tango Therapeutics has successfully raised $165M in a Series B at a $600M valuation led by Third Rock Ventures, BVF Partners, Boxer Capital, Casdin Capital.


Company Overview


Tango Therapeutics is a Biotech company headquartered in 100 Binney Street, Cambridge, MA 02142, founded in 2017 with 120+ employees.


Cancer therapeutics discovering synthetic lethal drug targets


Fundraising Details


  • Amount Raised: $165M
  • Round Type: Series B
  • Valuation: $600M
  • Date: 2024-02-12
  • Investors: Third Rock Ventures, BVF Partners, Boxer Capital, Casdin Capital

About Tango Therapeutics


Cancer therapeutics discovering synthetic lethal drug targets The company is positioned in the Biotech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 100 Binney Street, Cambridge, MA 02142
  • Founded: 2017
  • Team Size: 120+
  • Industry: Biotech

What This Means


This funding round demonstrates strong investor confidence in Tango Therapeutics's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Tango Therapeutics's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $600M valuation marks an important milestone for Tango Therapeutics, positioning the company among notable players in the Biotech industry.


Looking Ahead


With this new capital, Tango Therapeutics is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-02-12. For more information about Tango Therapeutics, visit their headquarters at 100 Binney Street, Cambridge, MA 02142.

Company Info

Headquarters
100 Binney Street, Cambridge, MA 02142
Founded
2017
Team Size
120+

Topics

Fundraising(2912)Series B(306)BiotechTango Therapeutics

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free